Abilify. Buy more. Save more.

BOSTON (AP) — Bristol-Myers Squibb Co. and a former subsidiary have agreed to pay more than $515 million to settle federal and state investigations into their drug marketing and pricing practices.
The civil settlement announced Friday re…

Bristol-Myers Squibb Co. will close a plant in western Puerto Rico that makes heart disease and diabetes medicine, eliminating 400 jobs, reports AP (Nov. 8, 2007). The closure, due to reduced demand for the medication, will be completed at the end of 2008, said spokeswoman Carmen Velez. The plant, operating for 36 years, produces Pravachol for heart disease and …
…

Abilify has been approved for the treatment of schizophrenia. The new antipsychotic, which is said to offer a combination of proven efficacy and a favorable side-effect profile, is being marketed in a joint arrangement involving Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc. Schizophrenia affects more than 2 million Americans.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

…

Abilify is an antipsychotic medication. It works by changing the actions of chemicals in the brain. Abilify is used for treatment the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adults.Buy cheap Abilify online without prescriptionBefore you take Abilify, tell your doctor if you regularly use o…

Bristol-Myers Squibb Co. has been given FDA approval of a new label for Sprycel. The new designation recommends a 100-mg starting dose for the product, which treats chronic myeloid leukemia. The company has also announced clearance of Abilify as the first medication for add-on treatment of major depressive disorder.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

…

* The FDA has approved Abilify[TM] tablets (aripiprazole), a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals. There is no cure for the devastating brain disorder affecting 2.2 million Americans, but it is treatable, and Abilify has demonstrated a favorable side-effect profile in clinical trials.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

Psychiatric drugs …

An oral solution formulation of Abilify (aripiprazole) is now available. Abilify is indicated for the treatment of schizophrenia and for the treatment of acute manic and mixed episodes associated with bipolar disorder. For more information, contact Otsuka America Pharmaceutical Inc., by visiting www.abilify.com,…

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., have launched ABILIFY[R] DISCMELT[TM] (aripiprazole) Orally Disintegrating Tablets, an oral form of the antipsychotic medication aripiprazole that disintegrates rapidly in the mouth. The FDA approved ABILIFY DISCMELT on June 7. For full prescribing information, including boxed warning, visit www.abilify.com.

Related Results

Abilify approvalAb…

Shared psychotic disorder has also been referred to by other names such as psychosis of association, contagious insanity, infectious insanity, double insanity, and communicated insanity. This disorder usually occurs only in…

Oct. 18, 2005 — A new generation of antipsychotic drugs may slightly increase the risk of death when used to treat common behavioral and psychological problems in people with dementia.
The new drugs include Abilify, Zyprexa, Seroquel, and Risperdal.
A new review of clinical trials that treated people with dementia shows 3.5% of those prescribed the drugs died compared with 2.3% of those who…